GlobeNewswire by notified

Benevity’s 2024 Corporate Goodness Awards Celebrate Groundbreakers in Social Impact

Share

Awards recognize purpose-driven brands for their extraordinary approaches to social impact, corporate philanthropy and employee engagement

PALM SPRINGS, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Benevity Inc., the leading global provider of social impact software, today announced the winners of its 2024 Corporate Goodness Awards, also known as “The Goodies,” acknowledging leading-edge brands for their innovative and inspirational approaches to social impact, employee engagement and corporate philanthropy. The 2024 Goodie Awards were presented to the winners on April 25 in Palm Springs, CA at Benevity Live!, the company’s flagship conference, which brings together more than 700 purpose-driven professionals to share insights and strategies about the future of corporate impact.

This year saw a record-breaking 197 nominations from 99 of the world’s most iconic and purpose-driven brands. The winners were recognized across various categories based on the innovative, inclusive and creative ways they are making a difference in the world through their giving, volunteering and community investment programs.

“The Goodie Awards winners and finalists are doing incredible things to challenge the status quo, catalyze positive action in meaningful ways and creatively solve critical issues facing society,” said Kelly Schmitt, Benevity’s Chief Executive Officer. “We are so inspired by these innovative companies and people for creating deeply impactful programs that truly reflect their core values.”

Companies who were selected as Goodies finalists contributed more than $153 million in donations and $7.9 million in grants and tracked more than 1.7 million volunteer hours through the Benevity platform in 2023.

Benevity’s 2024 Goodies Finalists and Winners

The Bestie Awards: For best-in-class approach and overall impact
The Bestie Award is selected from all finalists and recognizes the company with the best-in-class approach to corporate purpose, driving impact for their nonprofits, communities and employees.

  • USAA (WINNER for Enterprise)
  • Vancouver Airport Authority (WINNER for Mid-size)

The BeCause Award: For dedication to causes
The BeCause Award recognizes companies making a big impact on societal or community issues by removing barriers for nonprofits so they can operate with more autonomy, flexibility and speed.

  • eBay (WINNER)
  • HPE
  • Hootsuite
  • IBM
  • Robert Bosa Foundation

The Buzz Award: For catalyzing purpose through communications and storytelling
The Buzz Award recognizes companies that bring their corporate purpose programs to life, by embracing true storytelling over “numbertelling” and by sharing impact stories from employees, customers and/or nonprofits.

  • Elevance Health Foundation (WINNER)
  • Activision Blizzard
  • Ciena
  • Okta
  • Relativity

The Community Hero Award: For best in class approach to community investment
The Community Hero Award recognizes companies taking a strategic yet creative approach to community investment to create greater impact with its nonprofit partners.

  • DaVita (WINNER)
  • CSAA Insurance Group
  • Principal Financial Group
  • Sequoia Healthcare District
  • Vancouver Airport Authority

The Moonshot Award: For boldness and creativity
The Moonshot Award recognizes companies that have developed a creative, bold and impactful corporate purpose program and engages their communities, employees or customers in interesting ways to maximize their social and business impact.

  • Coast Capital Savings (WINNER)
  • First Tech Federal Credit Union
  • FTI Consulting
  • Gibson Energy
  • USAA

The NewB Award: For most transformative approach
The NewB Award recognizes new Benevity clients that have created significant impact through a best-in-class corporate purpose program launch and have implemented best practices to engage stakeholders.

  • Alberta Investment Management Corp. (WINNER)
  • ENMAX
  • KLA Foundation
  • Tractor Supply
  • Veritiv

The People Power Award: For promoting purpose through people’s passions
The People Power Award recognizes companies that build a culture powered by its people and creates significant impact by putting the power of goodness in the hands of employees to address critical issues.

  • Ciena (WINNER)
  • Appfire
  • F5
  • Gilead Foundation
  • Symetra Life Insurance Company

The Buffy Award: For individual leadership, innovation and impact
The Buffy Award celebrates outstanding individuals who exemplify passion, innovation, imagination and leadership in the corporate purpose space.

  • Kelly Petrich, Director, Community Impact, Cisco
  • Estelle Roth, Global Head Giving & Volunteering, Novartis

The Change Champion Award: For an executive who champions a purpose-driven culture
This new category celebrates an executive who is a shining example of what it looks like to lead with purpose. They foster diversity, equity and inclusion; they champion social action; and they inspire others with their commitment to purpose, people and profit.

  • Kristina Karnovsky, FactSet

Employee Catalyst Award: For an employee whose passion creates movements
The Employee Catalyst Award recognizes passionate employees who go beyond their day-to-day job to engage employees and community members in opportunities to do good, helping to fuel a culture of purpose.

  • Tom Mahatdejkul, ARM

Learn more about this year’s Goodie Awards winners and their exciting programs here.

About Benevity
Benevity, a certified B Corporation, is the leading global provider of social impact software, providing the only integrated suite of community investment and employee, customer and nonprofit engagement solutions. Recognized as one of Fortune’s Impact 20, Benevity offers cloud solutions that power purpose for many iconic brands in ways that better attract, retain and engage today’s diverse workforce, embed social action into their customer experiences and positively impact their communities. With software that is available in 22 languages, Benevity has processed more than $15 billion in donations and 79 million hours of volunteering time to support 470,000 nonprofits worldwide. The company’s solutions have also facilitated 1.3 million micro-actions and managed 845,000 grants worth $16 billion. For more information, visit benevity.com.

Media Contact:
Zamira Tasneem│Media & Communications Manager │ 1.416.451.6511 │ press@benevity.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Epiq Service Cloud Delivers Legal Workflow Gen AI Text Summarization6.5.2024 15:22:30 CEST | Press release

Advanced AI is accessible without the need for specialized AI knowledge NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Epiq, a global technology-enabled leader to the legal industry and corporations, today announced Gen AI Text Summarization within the Epiq Service Cloud. This latest feature, powered by Azure OpenAI Service, is adaptable and scalable to support a wide range of legal processes, including eDiscovery and investigations, deposition summaries, mediations, and trials. “Our Gen AI Text Summarization feature underscores Epiq’s commitment to making advanced technology accessible and practical for every legal professional without specialized AI knowledge,” said Eric Crawley, Senior Vice President, Legal Solutions at Epiq. “This feature brings efficiencies to a diverse set of legal workflows while maintaining high standards of accuracy.” The latest Gen AI advancement simplifies the review of complex documents to aid in early case assessment and enhance data analysis. Legal profession

Schouw & Co. aktietilbagekøbsprogram, uge 18 20246.5.2024 15:11:08 CEST | pressemeddelelse

Den 4. marts 2024 iværksatte Schouw & Co. et aktietilbagekøbsprogram som beskrevet i selskabsmeddelelse nr. 13 af 1. marts 2024. I henhold til programmet vil Schouw & Co. i perioden fra 4. marts 2024 til 31. december 2024 købe egne aktier for et maksimalt beløb på 200 mio. kr. Aktietilbagekøbsprogrammet gennemføres i henhold til Europa-Parlamentets og Rådets forordning (EU) nr. 596/2014 af 16. april 2014 om markedsmisbrug (MAR) og Kommissionens delegerede forordning (EU) 2016/1052 af 8. marts 2016 ("Safe Harbour”-reglerne). HandelsdagAntal aktierGennemsnitlig kursBeløb Akkumuleret indtil 26/4 2024 79.600 526,89 41.940.547 mandag 29. april 2024 1.900 529,73 1.006.487 tirsdag 30. april 2024 1.000 539,39 539.390 onsdag 1. maj 2024 1.000 555,04 555.040 torsdag 2. maj 2024 1.000 556,37 556.370 fredag 3. maj 2024 1.200 556,39 667.668 I perioden 29/4 2024 - 3/5 2024 6.100 545,07 3.324.955 Samlet i perioden 4/3 2024 - 3/5 2024 85.700 528,19 45.265.502 Ved periodens udløb ejer Schouw & Co. 2.19

Schouw & Co. share buy-back programme, week 18 20246.5.2024 15:11:08 CEST | Press release

On 4 March 2024, Schouw & Co. initiated a share buy-back programme as outlined in Company Announcement no. 13 of 1 March 2024. Under the programme, Schouw & Co. will acquire shares for up to DKK 200 million during the period 4 March 2024 to 31 December 2024. The buy-back will be structured in accordance with Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR) and the Commission’s delegated regulation (EU) 2016/1052 of 8 March 2016 (“Safe Harbour” rules). Trading dayNo. of sharesAverage priceAmount Accumulated until 26/4/2024 79,600 526.89 41,940,547 Monday, 29 April 2024 1,900 529.73 1,006,487 Tuesday, 30 April 2024 1,000 539.39 539,390 Wednesday, 1 May 2024 1,000 555.04 555,040 Thursday, 2 May 2024 1,000 556.37 556,370 Friday, 3 May 2024 1,200 556.39 667,668 In the period 29/4/2024 - 3/5/2024 6,100 545.07 3,324,955 Accumulated 4/3/2024 - 3/5/2024 85,700 528.19 45,265,502 Following the above transactions Schouw & Co. holds a

AKVA group ASA: Status buyback of own shares6.5.2024 14:57:37 CEST | Press release

As announced on 22 March 2024 AKVA group ASA ("AKVA group" or the "Company") has initiated repurchase of up to 200,000 of the company's own shares to be used in its share programme for employees. From 30 April through 6 May the company bought 10 855 shares at an weighted average price of NOK 65,8477. See the attached documents for detailed information about the transactions made. The company has bought a total of 57 896 shares at an weighted average price of NOK 68,3271 since 22 March. After these transactions, the company owns 288 559 treasury shares. This information is made public by the Company pursuant to the EU Market Abuse Regulation article 5, as supplemented by Commission Delegated Regulation (EU) 2016/1052 and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. Dated: 6 May 2024 AKVA group ASA Web: www.akvagroup.com CONTACTS: Knut Nesse Chief Executive OfficerPhone:+47 51 77 85 00Mobile:+47 91 37 62 20E-mail:knesse@akvagrou

AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®6.5.2024 14:30:00 CEST | Press release

OCALA, Fla., May 06, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of Ampligen® (rintatolimod), AIM’s dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. AIM Chief Executive Officer Thomas K. Equels commented, “We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials.” Ampligen is currently being evaluated as

HiddenA line styled icon from Orion Icon Library.Eye